Literature DB >> 22550434

The role of chemotherapy in the management of patients with head and neck cancer.

Panayiotis Panos Savvides1.   

Abstract

Recent advances in the management of patients with head and neck cancer point to an expanding role of chemotherapy, resulting in an increased involvement of the medical oncologist in the multidisciplinary care of these patients. This review focuses on patients with squamous cell carcinoma of the oral cavity, pharynx, and larynx. A comprehensive review of the clinical trial data that have defined new standards of care and a detailed presentation of widely used chemotherapeutic regimens, including both cytotoxic and molecularly targeted agents, are presented. Information on human papilloma virus-associated squamous cell cancer of the head and neck is presented, and implications in the clinical management of this subgroup of patients based on the epidemiologic and pathologic characteristics are discussed.

Entities:  

Keywords:  Cancer of the head and neck; chemotherapy; squamous cell carcinoma

Year:  2010        PMID: 22550434      PMCID: PMC3324245          DOI: 10.1055/s-0030-1255331

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.314


  88 in total

1.  Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer.

Authors:  J P Pignon; J Bourhis; C Domenge; L Designé
Journal:  Lancet       Date:  2000-03-18       Impact factor: 79.321

2.  A causal role for human papillomavirus in head and neck cancer.

Authors:  M L Gillison; D R Lowy
Journal:  Lancet       Date:  2004-05-08       Impact factor: 79.321

3.  Docetaxel: an active drug for squamous cell carcinoma of the head and neck.

Authors:  A I Dreyfuss; J R Clark; C M Norris; R M Rossi; J W Lucarini; P M Busse; M D Poulin; L Thornhill; R Costello; M R Posner
Journal:  J Clin Oncol       Date:  1996-05       Impact factor: 44.544

Review 4.  Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.

Authors:  Aimee R Kreimer; Gary M Clifford; Peter Boyle; Silvia Franceschi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-02       Impact factor: 4.254

5.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study.

Authors:  A A Forastiere; B Metch; D E Schuller; J F Ensley; L F Hutchins; P Triozzi; J A Kish; S McClure; E VonFeldt; S K Williamson
Journal:  J Clin Oncol       Date:  1992-08       Impact factor: 44.544

6.  Preliminary results of a randomized study on therapeutic gain by concurrent chemotherapy for regionally-advanced nasopharyngeal carcinoma: NPC-9901 Trial by the Hong Kong Nasopharyngeal Cancer Study Group.

Authors:  Anne W M Lee; W H Lau; Stewart Y Tung; Daniel T T Chua; Rick Chappell; L Xu; Lillian Siu; W M Sze; T W Leung; Jonathan S T Sham; Roger K C Ngan; Stephen C K Law; T K Yau; Joseph S K Au; Brian O'Sullivan; Ellie S Y Pang; S K O; Gordon K H Au; Joseph T Lau
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

7.  Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck.

Authors:  David I Rosenthal; Li Liu; Jason H Lee; Neha Vapiwala; Ara A Chalian; Gregory S Weinstein; Irina Chilian; Randal S Weber; Mitchell Machtay
Journal:  Head Neck       Date:  2002-02       Impact factor: 3.147

8.  Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Authors:  Sharon A Spencer; Jonathan Harris; Richard H Wheeler; Mitchell Machtay; Christopher Schultz; William Spanos; Marvin Rotman; Ruby Meredith; Kie-Kian Ang
Journal:  Head Neck       Date:  2008-03       Impact factor: 3.147

9.  Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.

Authors:  Dora L W Kwong; Jonathan S T Sham; Gordon K H Au; Daniel T T Chua; Philip W K Kwong; Ashley C K Cheng; P M Wu; Martin W M Law; Carol C H Kwok; C C Yau; K Y Wan; Raymond T T Chan; Damon D K Choy
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

10.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Authors:  Denis Soulieres; Neil N Senzer; Everett E Vokes; Manuel Hidalgo; Sanjiv S Agarwala; Lillian L Siu
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

View more
  1 in total

1.  The clinical significance of HOXA9 promoter hypermethylation in head and neck squamous cell carcinoma.

Authors:  Chongchang Zhou; Jinyun Li; Qun Li; Huigao Liu; Dong Ye; Zhenhua Wu; Zhisen Shen; Hongxia Deng
Journal:  J Clin Lab Anal       Date:  2019-03-06       Impact factor: 2.352

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.